MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
EMA

EMA

Emera Incorporated

$49.28
-0.1
 (-0.2%)
Exchange:  NYSE
Market Cap:  15.075B
Shares Outstanding:  247.8M
Delayed data
Calculate EMA Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  UtilitiesView sector performance
Industry:  Regulated ElectricView industry performance
   
CEO:  Scott Carlyle Balfour
Full Time Employees:  7812
Address: 
1223 Lower Water Street
Halifax
NS
B3J 3S8
CA
Website:  https://www.emera.com
Emera Incorporated, an energy and services company, invests in generation, transmission, and distribution of electricity in the United States, Canada, Barbados, and the Bahamas. The company operates through Florida Electric Utility, Canadian Electric Utilities, Gas Utilities and Infrastructure, Other Electric Utilities, and Other segments. It is involved in the purchase, transmission, distribution, and sale of natural gas; and physical energy marketing, trading, and other energy asset management activities. The company was incorporated in 1998 and is headquartered in Halifax, Canada.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
EMEMA logoEMAEmera Incorporated15.1B21.525.72.8%
KEKEP logoKEPKorea Electric Power Corporation14.1B2.74.03.9%
DUDUKB logoDUKBDuke Energy Corporation 5.625%16.2B17.93.14.2%
XEXELLL logoXELLLXcel Energy Inc. 6.25% Junior Subordin…13.3B20.6—3.7%
LNLNT logoLNTAlliant Energy Corporation16.9B21.219.14.0%
EVEVRG logoEVRGEvergy, Inc.18.4B20.318.74.5%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/08/07 — Q2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue7,563,0007,200,0008,302,228.713
Gross Profit3,284,0002,905,0002,040,335.904
EBITDA2,889,0002,505,0003,500,145.285
Operating Income1,794,0001,080,0001,554,731.962
Net Income1,044,000567,0001,088,112.536

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets39,480,00042,951,00044,780,477
Total Liabilities27,392,00029,660,00031,395,394
Total Stockholders Equity12,074,00013,277,00013,371,095
Total Debt19,856,00019,807,00021,619,367
Cash and Cash Equivalents588,000196,000364,703

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,241,0002,646,0001,800,531.488
Capital Expenditure-2,937,000-3,151,000-3,529,121.653
Free Cash Flow-696,000-505,000-1,728,590.164
Net Income1,044,000568,0001,088,112.536
Net Change in Cash256,000-367,000161,608.509

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)5,805,159.323Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)7,492,442.921Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)6,397,380Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)3,901,649.099Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)4,227,509.211Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)4,016,023.180Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)779,867.354Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)1,083,844.074Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)886,560.554Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)10,616.155Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)13,701.767Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)11,699.176Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)2.960Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)3.620Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)2.600Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
2.58
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
21.51
?Enterprise Value
 (TTM)
: 
42.569B  ?EV/FCF
 (TTM)
: 
-36.6
?Dividend Yield
 (TTM)
: 
4.3%  ?Payout Ratio
 (TTM)
: 
65.29%
?ROE
 (TTM)
: 
7.51%  ?ROIC
 (TTM)
: 
2.78%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
1.54
?P/B
 (TTM)
: 
1.45  ?Current Ratio
 (TTM)
: 
0.73

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
25.73Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about EMA valuation

Is Emera Incorporated (EMA) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Emera Incorporated (EMA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is EMA a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EMA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is EMA’s P/E ratio?

You can see EMA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for EMA?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is EMA a good long-term investment?

Whether EMA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

EMA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.2
MARKETSnap

Trading Metrics:

Open: 48.96   Previous Close: 49.38
Day Low: 48.66   Day High: 49.32
Year Low: 45.78   Year High: 55.49
Price Avg 50: 51.8   Price Avg 200: 51.29
Volume: 342834   Average Volume: 445792

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Engineers Gate Manager LP Purchases 17,165 Shares of eMagin Corporation $EMA
18-09-2026 03:25
Engineers Gate Manager LP Purchases 17,165 Shares of eMagin Corporation $EMA
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
18-06-2026 01:00
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
27-05-2026 06:00
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read